Added to YB: 2025-09-23
Pitch date: 2025-09-19
HCM [neutral]
HUTCHMED (China) Limited
-21.57%
current return
Author Info
Increasing Odds shares their investment journey in their newsletter. Sign up for the newsletter.
Company Info
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally.
Market Cap
GBP 3.0B
Pitch Price
GBP 2.55
Price Target
N/A
Dividend
N/A
EV/EBITDA
52.08
P/E
6.49
EV/Sales
2.82
Sector
Pharmaceuticals
Category
N/A
Exploring AIM: A-Z Part 16 - Pass: HUTCHMED (China) Limited
HCM pass: Chinese cancer drug discovery co w/ manufacturing. £2.2b mcap, -10% rev decline, expects flat FY. Near breakeven but >50% mcap in cash from $477M JV divestment. CK Hutchinson owns 38%. China + biotech exposure = pass.
Read full article (1 min)